Gwang-Ho Kim
Ufficiale delle Risorse Umane presso GENEXINE, INC.
Provenienza dei contatti di primo grado di Gwang-Ho Kim
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
| Public Company | Biotechnology | 4 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Gwang-Ho Kim tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
| HANDOK INC. | Pharmaceuticals: Other | Chief Executive Officer | |
| MERRIMACK PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| McGill University | College/University | Masters Business Admin | |
| Northern Illinois University | College/University | Doctorate Degree | |
| University of Wisconsin | College/University | Doctorate Degree | |
| Yonsei University | College/University | Undergraduate Degree | |
| Hoechst Marion Roussel, Inc. | Chief Executive Officer | ||
Elan Biopharmaceuticals, Inc.
 Elan Biopharmaceuticals, Inc. Medical DistributorsDistribution Services Elan Biopharmaceuticals, Inc. distributes drugs and pharmaceuticals. It currently distributes three concentrated morphine sulfate oral solutions which include RoxanolT CII, Roxanol-TT CII and Roxanol 100T CII. Elan Biopharmaceuticals is located in San Diego, CA. | Medical Distributors | Sales & Marketing | |
The Korea Chamber of Commerce & Industry
 The Korea Chamber of Commerce & Industry Miscellaneous Commercial ServicesCommercial Services The Korea Chamber of Commerce & Industry (KCCI) is a business organization that provides resources, publications, events, and networks for its members. The organization is based in Seoul, North Korea and has overseas offices. The KCCI advocates for its members and partners with other organizations to promote bilateral economic cooperation. The KCCI also provides economic data and policy issues publications and hosts business forums and roundtables. Recently, the KCCI hosted a successful business forum with over 600 attendees, including political and business leaders from both countries. The Financial Services Commission identified five bank holding companies and five banks as domestic systemically important banks for 2024, and those identified as D-SIBs are required to set aside an additional common equity capital of 1.0, and the higher loss absorbency requirement will take effect on January 1, 2024. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| Korea Pharmaceutical Manufacturers Association | Director/Board Member | ||
| REZOLUTE, INC. | Pharmaceuticals: Major | Director/Board Member | |
| Kelley School of Business | College/University | Masters Business Admin | |
| Handok Jeseok Foundation | President | ||
pH Pharma Co., Ltd.
 pH Pharma Co., Ltd. Pharmaceuticals: MajorHealth Technology pH Pharma Co. Ltd. engages in the developing and manufacturing of bio-pharmaceuticals. Its products include php-303, php-201, ab-101, nuvesse, alpine and torpedo products. The company was founded by Ho Young Huh on September 22, 2015 and is headquartered in Seoul, South Korea. | Pharmaceuticals: Major | Director/Board Member | |
TRIGR Therapeutics, Inc.
 TRIGR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trigr Therapeutics, Inc. engages in pharmaceuticals industry group. The company is headquartered in Irvine, CA. | Pharmaceuticals: Major | Director/Board Member | |
PT Kalbe Genexine Biologics
 PT Kalbe Genexine Biologics BiotechnologyHealth Technology PT Kalbe Genexine Biologics is a clinical-stage biotech company based in Jakarta, Indonesia. The Indonesian company specializes in licensing novel biologics and biosimilars in oncology and high-specialty therapeutic areas, as well as contract manufacturing. The company was founded in 2016 and is backed by Kalbe and Genexine, as well as US private equity giant General. The CEO is Sie Djohan. | Biotechnology | Chief Operating Officer | |
| Korea Hoechst Marion Roussel | Chief Executive Officer | ||
| Korean German Society | President | ||
| Korean German Chamber of Commerce & Industry | Director/Board Member | ||
Sanofi-Aventis Korea Co., Ltd.
 Sanofi-Aventis Korea Co., Ltd. Pharmaceuticals: MajorHealth Technology Sanofi-Aventis Korea Co., Ltd. provides pharmaceutical research and development services. Its products include prescription medicine, consumer health care, vaccines, and non-prescription medicine. The company founded in April 1991 and is headquartered in Seoul, South Korea. | Pharmaceuticals: Major | Chief Executive Officer | |
| CHONG KUN DANG PHARMACEUTICAL CORP. | Pharmaceuticals: Major | Chief Executive Officer |
Statistiche
Distribuzione geografica
| Corea del Sud | 11 |
| Stati Uniti | 9 |
| Germania | 3 |
| Canada | 2 |
| Indonesia | 2 |
Settori
| Health Technology | 9 |
| Consumer Services | 6 |
| Process Industries | 2 |
| Distribution Services | 2 |
| Electronic Technology | 2 |
Posizioni
| Director/Board Member | 10 |
| Chief Executive Officer | 5 |
| Corporate Officer/Principal | 5 |
| Chairman | 3 |
| Independent Dir/Board Member | 3 |
Contatti più connessi
| Insiders | |
|---|---|
| Young-Jin Kim | 15 |
| Peter N. Laivins | 4 |
| Kyu-Don Kim | 4 |
| Jin-Geon Bae | 4 |
- Borsa valori
- Insiders
- Gwang-Ho Kim
- Connessioni Società
